• Aptevo Therapeutics reported results showing mipletamig with venetoclax and azacitidine enabled newly diagnosed AML patients to reach potentially curative stem cell transplants.
• The findings cover the ongoing Phase 1b RAINIER trial and a completed dose-expansion study involving patients initially considered unfit for intensive chemotherapy.
• RAINIER dosing evaluation is expected to finish by year-end 2026, with regulatory discussions on next steps planned for the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610260805ACCESSWRNAPR_____1241458) on October 26, 2026, and is solely responsible for the information contained therein.